Medicus pharma provides update on sknjct-003 phase 2 clinical study for the treatment of nodular basal cell carcinoma (bcc)

The institutional review board has approved the increase in number of patients from sixty (60) to ninety (90). the company to expand the study into additional trial sites in europe philadelphia, pennsylvania--(newsfile corp. - april 21, 2025) - medicus pharma ltd.
BCC Ratings Summary
BCC Quant Ranking